Industry / Israel
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Proposed IP Improvements Run Into Opposition
December 2007 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Opposition from leading generic drugmakers, principally Teva Pharmaceutical Industries, has put into doubt government plans to improve Israel's intellectual property (IP) environment according to local newspaper the Jerusalem Post. BMI's hopes had been raised by news in November that Minister of Industry, Trade and Labour Eli Yishai had set up an inter-ministerial team to review the issues surrounding any decision to improve the country's lax IP laws. However, as could be expected, powerful opponents have raised their voices and the process seems to have become increasingly clouded by a war of words between parties with competing